PC
IOVA icon

PointState Capital’s Iovance Biotherapeutics IOVA Stock Holding History

PointState Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-295,800
Closed -$5M – 185
2018
Q1 		$5M Buy
+295,800
New +$4.48M 0.05% 113

Other funds holding IOVA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PointState Capital's IOVA Position: Q2 2018 in Review

PointState Capital sold out of Iovance Biotherapeutics (IOVA) in Q2 2018, closing a stake of 295,800 shares — an estimated $5M sold.

PointState Capital first reported a position in IOVA in Q1 2018 and held it in 1 quarter. The position peaked at $5M in Q1 2018. 126 funds tracked by Wall St. Rank hold IOVA as of Q2 2018.

  • PointState Capital reported no remaining Iovance Biotherapeutics position as of Q2 2018 after selling out during the quarter.
  • PointState Capital sold 295,800 Iovance Biotherapeutics shares in Q2 2018, an estimated $5M.
  • PointState Capital first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 1 quarter.
  • PointState Capital's Iovance Biotherapeutics position peaked at $5M in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2018.

Based on PointState Capital's 13F filing for Q2 2018, filed 14 Aug 2018.